As pointed out by others, B cells are deemed as much safer than T cells - so safety is unlikely to be an issue.
We have B cells naturally in our body that does this very job, the T cells are synthetic. The patients aren't given that many B cells, your own body produces the correct amount, in theory.
I once asked Leslie about the different cohorts and if it was irrelevant, as your own body makes them after getting a jump start from imu. She replied "Interrogating these hypothesis is critical in this clinical trial".
But there is always risk.
The sp action suggests that there is no problem at all, quite the reverse.
As for the meeting in Vienna, who knows. I would have thought a safety issue would mean meeting asap, trial put on hold and market informed etc.
Interesting that they pulled out of a conference too. VLA pulled out of one of the big cancer meetings set for April (from memory). A few weeks later the Merck deal came.
Nice from ivx today. I still can't believe the market hasn't spotted ptx yet. Loads of near big term news, lots of promise, $18m mkt cap and $6m in the bank. Should be double at least!
Add to My Watchlist
What is My Watchlist?
